THE Therapeutic Goods Administration (TGA) yesterday advised of recent reports, both in Australia and overseas, which indicate that peripheral neuropathy may occur at a daily dose of less than 50mg a day of vitamin B6 (pyridoxine).
Issues have also been reported in consumers taking more than one product containing B6, with the TGA currently reviewing the issue.
"The outcome of this review may result in changes to the requirements for medicines that contain vitamin B6," the TGA said.
There are currently more than 1,000 listed medicines in Australia containing pyridoxine, and currently only products containing over 50mg are required to have a warning about potential tingling, burning or numbness.
Consumers and health professionals are urged to be aware that peripheral neuropathy can occur at doses of less than 50mg of vitamin B6 per day, and patients presenting with symptoms should be reviewed for vitamin B6 intake from sources such as B vitamins, multivitamins and/or magnesium products.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 May 20
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 May 20